Valneva For 2024 Expects Total Revenues Of €170M-€190M And R&D Investments Between €60M-€75M

Valneva預計2024年的總收入爲1.7億至1.9億歐元，研發投資在6000萬至7500萬歐元之間

Benzinga · 05/07 13:47

2024 financial guidance confirmed

2024 年財務指引已確認

Expected total revenues between €170 million and €190 million, including:
- €160 million to €180 million of sales driven by growth of Valneva's proprietary products

預計總收入在1.7億歐元至1.9億歐元之間，包括：
- 在Valneva專有產品的增長推動下，銷售額爲1.6億至1.8億歐元

Expected R&D investments between €60 million and €75 million, mostly dedicated to ongoing chikungunya development activities, the Zika trial and advancement of pre-clinical programs
Expected Other income between €100 million and €110 million, reflecting €95 million in proceeds from the PRV sale

預計研發投資在6000萬歐元至7500萬歐元之間，主要用於正在進行的基孔肯雅熱開發活動、寨卡試驗和臨床前項目的推進
預計其他收入介於1億歐元至1.1億歐元之間，反映了9,500萬歐元的PRV出售收益

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。